Arcus Biosciences, Inc.
3928 Point Eden Way
Hayward
California
94545
United States
Tel: 510-694-6000
Website: http://www.arcusbio.com/
Email: jobs@arcusbio.com
About Arcus Biosciences, Inc.
Arcus was founded in 2015 with the vision of bringing together scientists, physicians, advisors, and other leaders with significant content-matter expertise to focus on developing highly-combinable, best-in-class cancer therapies. The complexity of the tumor microenvironment requires a deep scientific understanding to guide judicious combinations of therapeutic agents with potential synergistic activity and the ability to identify biomarkers to select patients most likely to achieve significant, durable responses to treatment. Since our inception, our focus has primarily been targeting well-understood biological pathways where the biology had not yet yielded high-quality medicines.
One of Arcus's early key competitive advantages was building a strong foundation of an industry-leading group of individuals who run our world-class discovery engine and development organization. We believe discovery is not a commodity and have invested in building a high-performing research organization. Through the efforts of our discovery and development teams, we were able to bring our first molecule in the clinic from concept to the clinical stage development in less than 21 months.
We have complemented our productive discovery organization with clinical and commercial leadership that has led multiple cancer immunotherapy programs from early-stage development though to successful global launches. As Arcus advances its product candidates through clinical studies, we work closely with the medical community, patients and caregivers to facilitate participation in our clinical trials enabling potential breakthrough medicines to reach patients faster.
Today, with four product candidates in the clinic across more than a dozen clinical studies in areas of high unmet need, we are well on our way to becoming a fully integrated biopharmaceutical company creating best-in-class cancer therapies.
Stock Symbol: RCUS
Stock Exchange: NYSE
76 articles with Arcus Biosciences, Inc.
-
Arcus Biosciences Announces New Employment Inducement Grants - Sep 10, 2020
9/10/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 120,500 shares of the Company’s common stock at an exercise price per share of $20.71, which was the closing price on September 8, 2020.
-
Arcus Biosciences to Participate in Upcoming September 2020 Investor Conferences
8/27/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences:
-
Arcus Biosciences Announces New Employment Inducement Grants - Aug 11, 2020
8/11/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted eleven new employees options to purchase a total of 135,900 shares of the Company’s common stock at an exercise price per share of $22.96, which was the closing price on August 10, 2020.
-
Arcus Biosciences Announces Second Quarter 2020 Financial Results and Corporate Updates
8/6/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the second quarter ended June 30, 2020 and provided corporate updates.
-
Arcus Biosciences Announces New Employment Inducement Grant
8/4/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, as previously disclosed in its Form 8-K filed with the Securities and Exchange Commission on July 7, 2020, the company made an inducement grant to Robert C. Goeltz II, the newly-appointed Chief Financial Officer of Arcus
-
Arcus Biosciences to Participate in Upcoming August Investor Conferences
7/28/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming virtual investor conferences
-
Gilead Sciences and Arcus Biosciences Complete Closing of Their 10-Year Partnership to Co-Develop and Co-Commercialize Next-Generation Cancer Immunotherapies
7/13/2020
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapeutics, announced today the closing of their option and co-development and co-commercialization partnership agreement signed on May 27, 2020.
-
Arcus Biosciences Announces New Employment Inducement Grants - July 09, 2020
7/9/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted ten new employees options to purchase a total of 190,200 shares of the Company’s common stock at an exercise price per share of $25.28, which was the closing price on July 8, 2020.
-
Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer
7/7/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020
-
Arcus Biosciences Announces New Employment Inducement Grants - June 09, 2020
6/9/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 138,000 shares of the Company’s common stock at an exercise price per share of $28.96, which was the closing price on June 8, 2020.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Arcus Biosciences to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
6/3/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Wednesday, June 10, 2020 at 3:50 p.m. Eastern Time.
-
Arcus Biosciences, Inc. Announces Pricing of $302.5 Million Underwritten Public Offering of Common Stock
5/28/2020
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $27.50 per share
-
Arcus Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
5/27/2020
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock.
-
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
5/27/2020
Arcus to Continue to Independently Conduct Research on New Targets; Gilead to Receive Rights to Opt-In to All Programs in Arcus’s Pipeline for Length of Collaboration
-
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’s pipeline products.
-
Arcus Biosciences Appoints David Lacey, M.D., to Its Board of Directors
5/26/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company’s Board of Directors
-
Arcus Biosciences Announces New Employment Inducement Grants - May 11, 2020
5/11/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 56,000 shares of the Company’s common stock at an exercise price per share of $30.08, which was the closing price on May 8, 2020.
-
Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates
5/5/2020
AB680, the first small-molecule CD73 inhibitor in the clinic, continues in a Phase 1 dose-escalation combination trial for first-line treatment of pancreatic cancer, with a recommended dose for expansion anticipated to be established in mid-2020
-
Arcus Biosciences Announces New Employment Inducement Grants - April 9, 2020
4/9/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 381,200 shares of the Company’s common stock at an exercise price per share of $15.32, which was the closing price on April 8, 2020.